GLP-1 Market Size, Share, & Industry Analysis Report : By Route of Administration (Oral, Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, By Region

Description

List of Tables

The GLP-1 Market size is expected to reach USD 133.92 billion by 2034, according to a new study by Polaris Market Research. The report "GLP-1 Market Share, Size, Trends, Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a major role in glucose metabolism. It allows insulin release and incorporates glucagon secretion. Therapeutically, GLP-1 receptor agonists are used to treat type 2 diabetes and support weight management. There is a growing use of these therapies into chronic disease management. Beyond type 2 diabetes, they are used to manage conditions such as obesity and cardiovascular risk. GLP-1 receptor agonists are being adopted as multi-targeted agents that align with evolving treatment guidelines as their clinical benefits become more widely recognized. This expanded utility is promoting greater interest among healthcare providers and patients seeking holistic, outcome-driven care solutions.

The continuous innovation led by pharmaceutical companies aims to improve drug delivery, convenience, and patient compliance. Companies are increasingly investing in next-generation formulations and combination therapies. It helps improve metabolic outcomes with fewer side effects and lower dosing frequency. Also, a growing focus on personalized treatment encourages the development of precision-based GLP-1 therapies tailored to patient profiles. These advancements collectively point to a shift in the market toward more personalized and long-term disease control strategies.

GLP-1 Market Report Highlights

In terms of type of GLP-1 agonist drugs, long-acting GLP-1 agonists led the market in 2025. The dominance is driven by their extended dosing intervals and consistent clinical outcomes.

By route of administration, the oral GLP-1 segment is anticipated to grow fastest during the forecast period. Increasing preference for needle-free, convenient treatment alternatives drives the growth.

In 2025, North America led the global market revenue share. High diabetes/obesity rates and advanced healthcare systems support market growth. Rapid uptake of innovative therapies also fueled the expansion.

Asia Pacific is expected to register the highest growth rate during the forecast period. The growth is fueled by surging prevalence of lifestyle-related metabolic disorders

A few global key market players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

Where is the GLP-1 Market Headed?

The rising preference for convenient treatment formats, particularly oral GLP-1 therapies and digitally supported care delivery, will transform the market. Oral formulations improve treatment accessibility for patients who are reluctant to begin injectable therapies. Telehealth, e-prescriptions, and direct-to-patient delivery models are improving prescription continuity. This trend is expected to support the online pharmacy and retail pharmacy segments, especially in chronic weight management and diabetes care.

Another major market trend is the shift from shortage-led demand distortion toward more normalized branded supply conditions. According to FDA updates in 2025, semaglutide injection shortage conditions have been resolved. The agency also increased scrutiny of unapproved or compounded GLP-1 products. This has important implications for market structure, pricing, patient trust, and channel strategy. Such factors will favor regulated and established supply pathways.

What GLP-1 Market Report Reveals?

What is the global market size, share, and CAGR for the market through 2034?

What are the market drivers, opportunities, trends, and restraints of the market growth?

Who are the key players, and what is their relative position in terms of competitive positioning?

How are the innovations and product pipelines of different players?

How does the demand for different types of molecules influence the market landscape?

How does the market differ in type of molecule, active compound used, type of GLP-1 agonist drug, route of administration, target indication, and geography, and which is the leading application?

What are the trends in the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?

Polaris Market Research has segmented the market report on the basis of type of molecule, active compound used, type of GLP-1 agonist drug, route of administration, target indication, and region:

By Type of Molecule Outlook (Revenue, USD Billion, 2021-2034)

Biologics

Small Molecules

By Active Compound Used Outlook (Revenue, USD Billion, 2021-2034)

Dulaglutide

Liraglutide

Orforglipron

Retatrutide

Semaglutide

Survodutide

Tirzepatide

Other Active Compounds

By Type of GLP-1 Agonist Drugs Outlook (Revenue, USD Billion, 2021-2034)

Long-acting GLP-1 Agonist

Short-acting GLP-1 Agonist

By Route of Administration Outlook (Revenue, USD Billion, 2021-2034)

Oral

Parenteral

By Target Indication Outlook (Revenue, USD Billion, 2021-2034)

Alzheimer's Disease

Non-Alcoholic Steatohepatitis

Obesity

Sleep Apnea

Type 2 Diabetes

By Regional Outlook (Revenue, USD Billion, 2021-2034)

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Product Code: PM5759

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global GLP-1 Market Insights

4.1. GLP-1 Market - Material Snapshot
4.2. GLP-1 Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising prevalence of type 2 diabetes globally
  - 4.2.1.2. Increasing rates of obesity and related metabolic disorders
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High cost of GLP-1 drugs and affordability challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. GLP-1 Market Material Trends
4.6. Value Chain Analysis

5. Global GLP-1 Market, by Type of Molecule

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global GLP-1 Market, by Type of Molecule, 2021-2034 (USD Billion)
5.3. Biologics
- 5.3.1. Global GLP-1 Market, by Biologics, by Region, 2021-2034 (USD Billion)
5.4. Small Molecules
- 5.4.1. Global GLP-1 Market, by Small Molecules, by Region, 2021-2034 (USD Billion)

6. Global GLP-1 Market, by Active Compound Used

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global GLP-1 Market, by Active Compound Used, 2021-2034 (USD Billion)
6.3. Dulaglutide
- 6.3.1. Global GLP-1 Market, by Dulaglutide, by Region, 2021-2034 (USD Billion)
6.4. Liraglutide
- 6.4.1. Global GLP-1 Market, by Liraglutide, by Region, 2021-2034 (USD Billion)
6.5. Orforglipron
- 6.5.1. Global GLP-1 Market, by Orforglipron, by Region, 2021-2034 (USD Billion)
6.6. Retatrutide
- 6.6.1. Global GLP-1 Market, by Retatrutide, by Region, 2021-2034 (USD Billion)
6.7. Semaglutide
- 6.7.1. Global GLP-1 Market, by Semaglutide, by Region, 2021-2034 (USD Billion)
6.8. Survodutide
- 6.8.1. Global GLP-1 Market, by Survodutide, by Region, 2021-2034 (USD Billion)
6.9. Tirzepatide
- 6.9.1. Global GLP-1 Market, by Tirzepatide, by Region, 2021-2034 (USD Billion)
6.10. Other Active Compounds
- 6.10.1. Global GLP-1 Market, by Other Active Compounds, by Region, 2021-2034 (USD Billion)

7. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
7.3. Long-acting GLP-1 Agonist
- 7.3.1. Global GLP-1 Market, by Long-acting GLP-1 Agonist, by Region, 2021-2034 (USD Billion)
7.4. Short-acting GLP-1 Agonist
- 7.4.1. Global GLP-1 Market, by Short-acting GLP-1 Agonist, by Region, 2021-2034 (USD Billion)

8. Global GLP-1 Market, by Route of Administration

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
8.3. Oral
- 8.3.1. Global GLP-1 Market, by Oral, by Region, 2021-2034 (USD Billion)
8.4. Parenteral
- 8.4.1. Global GLP-1 Market, by Parenteral, by Region, 2021-2034 (USD Billion)

9. Global GLP-1 Market, by Target Indication

9.1. Key Findings
9.2. Introduction
- 9.2.1. Global GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
9.3. ALZHEIMER'S DISEASE
- 9.3.1. Global GLP-1 Market, by ALZHEIMER'S DISEASE, 2021-2034 (USD Billion)
9.4. Non-Alcoholic Steatohepatitis
- 9.4.1. Global GLP-1 Market, by Non-Alcoholic Steatohepatitis, 2021-2034 (USD Billion)
9.5. Obesity
- 9.5.1. Global GLP-1 Market, by Obesity, 2021-2034 (USD Billion)
9.6. Sleep Apnea
- 9.6.1. Global GLP-1 Market, by Sleep Apnea, 2021-2034 (USD Billion)
9.7. Type 2 Diabetes
- 9.7.1. Global GLP-1 Market, by Type 2 Diabetes, 2021-2034 (USD Billion)

10. Global GLP-1 Market, by Geography

10.1. Key Findings
10.2. Introduction
- 10.2.1. GLP-1 Market Assessment, By Geography, 2021-2034 (USD Billion)
10.3. GLP-1 Market - North America
- 10.3.1. North America: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
- 10.3.2. North America: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
- 10.3.3. North America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
- 10.3.4. North America: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
- 10.3.5. North America: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.3.6. GLP-1 Market - US
  - 10.3.6.1. US: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.3.6.2. US: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.3.6.3. US: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.3.6.4. US: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.3.6.5. US: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.3.7. GLP-1 Market - Canada
  - 10.3.7.1. Canada: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.3.7.2. Canada: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.3.7.3. Canada: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.3.7.4. Canada: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.3.7.5. Canada: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
10.4. GLP-1 Market - Europe
- 10.4.1. Europe: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
- 10.4.2. Europe: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
- 10.4.3. Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
- 10.4.4. Europe: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
- 10.4.5. Europe: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.6. GLP-1 Market - UK
  - 10.4.6.1. UK: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.6.2. UK: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.6.3. UK: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.6.4. UK: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.6.5. UK: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.7. GLP-1 Market - France
  - 10.4.7.1. France: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.7.2. France: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.7.3. France: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.7.4. France: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.7.5. France: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.8. GLP-1 Market - Germany
  - 10.4.8.1. Germany: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.8.2. Germany: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.8.3. Germany: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.8.4. Germany: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.8.5. Germany: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.9. GLP-1 Market - Italy
  - 10.4.9.1. Italy: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.9.2. Italy: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.9.3. Italy: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.9.4. Italy: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.9.5. Italy: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.10. GLP-1 Market - Spain
  - 10.4.10.1. Spain: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.10.2. Spain: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.10.3. Spain: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.10.4. Spain: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.10.5. Spain: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.11. GLP-1 Market - Netherlands
  - 10.4.11.1. Netherlands: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.11.2. Netherlands: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.11.3. Netherlands: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.11.4. Netherlands: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.11.5. Netherlands: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.12. GLP-1 Market - Russia
  - 10.4.12.1. Russia: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.12.2. Russia: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.12.3. Russia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.12.4. Russia: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.12.5. Russia: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.4.13. GLP-1 Market - Rest of Europe
  - 10.4.13.1. Rest of Europe: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.4.13.2. Rest of Europe: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.4.13.3. Rest of Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.4.13.4. Rest of Europe: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.4.13.5. Rest of Europe: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
10.5. GLP-1 Market - Asia Pacific
- 10.5.1. Asia Pacific: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
- 10.5.2. Asia Pacific: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
- 10.5.3. Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
- 10.5.4. Asia Pacific: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
- 10.5.5. Asia Pacific: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.6. GLP-1 Market - China
  - 10.5.6.1. China: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.6.2. China: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.6.3. China: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.6.4. China: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.6.5. China: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.7. GLP-1 Market - India
  - 10.5.7.1. India: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.7.2. India: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.7.3. India: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.7.4. India: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.7.5. India: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.8. GLP-1 Market - Malaysia
  - 10.5.8.1. Malaysia: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.8.2. Malaysia: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.8.3. Malaysia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.8.4. Malaysia: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.8.5. Malaysia: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.9. GLP-1 Market - Japan
  - 10.5.9.1. Japan: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.9.2. Japan: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.9.3. Japan: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.9.4. Japan: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.9.5. Japan: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.10. GLP-1 Market - Indonesia
  - 10.5.10.1. Indonesia: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.10.2. Indonesia: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.10.3. Indonesia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.10.4. Indonesia: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.10.5. Indonesia: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.11. GLP-1 Market - South Korea
  - 10.5.11.1. South Korea: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.11.2. South Korea: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.11.3. South Korea: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.11.4. South Korea: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.11.5. South Korea: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.12. GLP-1 Market - Australia
  - 10.5.12.1. Australia: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.12.2. Australia: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.12.3. Australia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.12.4. Australia: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.12.5. Australia: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.5.13. GLP-1 Market - Rest of Asia Pacific
  - 10.5.13.1. Rest of Asia Pacific: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.5.13.2. Rest of Asia Pacific: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.5.13.3. Rest of Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.5.13.4. Rest of Asia Pacific: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.5.13.5. Rest of Asia Pacific: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
10.6. GLP-1 Market - Middle East & Africa
- 10.6.1. Middle East & Africa: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
- 10.6.2. Middle East & Africa: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
- 10.6.3. Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
- 10.6.4. Middle East & Africa: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
- 10.6.5. Middle East & Africa: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.6.6. GLP-1 Market - Saudi Arabia
  - 10.6.6.1. Saudi Arabia: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.6.6.2. Saudi Arabia: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.6.6.3. Saudi Arabia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.6.6.4. Saudi Arabia: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.6.6.5. Saudi Arabia: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.6.7. GLP-1 Market - UAE
  - 10.6.7.1. UAE: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.6.7.2. UAE: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.6.7.3. UAE: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.6.7.4. UAE: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.6.7.5. UAE: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.6.8. GLP-1 Market - Israel
  - 10.6.8.1. Israel: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.6.8.2. Israel: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.6.8.3. Israel: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.6.8.4. Israel: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.6.8.5. Israel: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.6.9. GLP-1 Market - South Africa
  - 10.6.9.1. South Africa: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.6.9.2. South Africa: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.6.9.3. South Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.6.9.4. South Africa: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.6.9.5. South Africa: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.6.10. GLP-1 Market - Rest of Middle East & Africa
  - 10.6.10.1. Rest of Middle East & Africa: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.6.10.2. Rest of Middle East & Africa: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.6.10.3. Rest of Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.6.10.4. Rest of Middle East & Africa: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.6.10.5. Rest of Middle East & Africa: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
10.7. GLP-1 Market - Latin America
- 10.7.1. Latin America: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
- 10.7.2. Latin America: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
- 10.7.3. Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
- 10.7.4. Latin America: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
- 10.7.5. Latin America: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.7.6. GLP-1 Market - Mexico
  - 10.7.6.1. Mexico: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.7.6.2. Mexico: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.7.6.3. Mexico: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.7.6.4. Mexico: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.7.6.5. Mexico: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.7.7. GLP-1 Market - Brazil
  - 10.7.7.1. Brazil: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.7.7.2. Brazil: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.7.7.3. Brazil: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.7.7.4. Brazil: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.7.7.5. Brazil: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.7.8. GLP-1 Market - Argentina
  - 10.7.8.1. Argentina: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.7.8.2. Argentina: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.7.8.3. Argentina: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.7.8.4. Argentina: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.7.8.5. Argentina: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)
- 10.7.9. GLP-1 Market - Rest of Latin America
  - 10.7.9.1. Rest of Latin America: GLP-1 Market, By Type of Molecule, 2021-2034 (USD Billion)
  - 10.7.9.2. Rest of Latin America: GLP-1 Market, By Active Compound Used, 2021-2034 (USD Billion)
  - 10.7.9.3. Rest of Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2021-2034 (USD Billion)
  - 10.7.9.4. Rest of Latin America: GLP-1 Market, by Route of Administration, 2021-2034 (USD Billion)
  - 10.7.9.5. Rest of Latin America: GLP-1 Market, by Target Indication, 2021-2034 (USD Billion)

11. Competitive Landscape

11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

12.1. AstraZeneca
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
12.2. Boehringer Ingelheim
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
12.3. D&D Pharmatech
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
12.4. Eli Lilly
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
12.5. Hanmi Pharmaceutical
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
12.6. Novo Nordisk
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
12.7. Pfizer
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
12.8. Roche
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
12.9. Sanofi
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
12.10. Tonghua Dongbao Pharmaceutical
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development